Molecular Modeling in Drug Design
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Rdock Reference Guide Rdock Development Team August 27, 2015 Contents
rDock Reference Guide rDock Development Team August 27, 2015 Contents 1 Preface 4 2 Acknowledgements 4 3 Introduction 4 4 Configuration 4 5 Cavity mapping 6 5.1 Two sphere method . 6 5.2 Reference ligand method . 8 6 Scoring function reference 11 6.1 Component Scoring Functions . 11 6.1.1 van der Waals potential . 11 6.1.2 Empirical attractive and repulsive polar potentials . 11 6.1.3 Solvation potential . 12 6.1.4 Dihedral potential . 13 6.2 Intermolecular scoring functions under evaluation . 13 6.2.1 Training sets . 13 6.2.2 Scoring Functions Design . 13 6.2.3 Scoring Functions Validation . 14 6.3 Code Implementation . 15 7 Docking protocol 17 7.1 Protocol Summary . 17 7.1.1 Pose Generation . 17 7.1.2 Genetic Algorithm . 17 7.1.3 Monte Carlo . 17 7.1.4 Simplex . 18 7.2 Code Implementation . 18 7.3 Standard rDock docking protocol (dock.prm) . 18 8 System definition file reference 22 8.1 Receptor definition . 22 8.2 Ligand definition . 23 8.3 Solvent definition . 24 8.4 Cavity mapping . 25 8.5 Cavity restraint . 27 8.6 Pharmacophore restraints . 27 8.7 NMR restraints . 28 8.8 Example system definition files . 28 9 Molecular files and atoms typing 30 9.1 Atomic properties. 30 9.2 Difference between formal charge and distributed formal charge . 30 9.3 Parsing a MOL2 file . 31 9.4 Parsing an SD file . 31 9.5 Assigning distributed formal charges to the receptor . 31 10 rDock file formats 32 10.1 .prm file format . -
Binding Kinetics Calculations of the Inclusion of Some Benzoic Acid Derivatives and Paracetamol in Β CD Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel
Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel To cite this version: Djamel Khatmi, Belgacem Bezzina, Stéphane Humbel. Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD. Journal of Inclusion Phenomena and Macrocyclic Chemistry, Springer Verlag, 2020, 96 (3-4), pp.373-379. 10.1007/s10847-020-00976-1. hal-02922032 HAL Id: hal-02922032 https://hal.archives-ouvertes.fr/hal-02922032 Submitted on 25 Aug 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Binding kinetics calculations of the inclusion of some benzoic acid derivatives and paracetamol in β CD. Djamel Eddine Khatmi,a, b* Belgacem Bezzina, b, c Stéphane Humbel,a a- Aix Marseille University, CNRS, Centrale Marseille, iSm2, Marseille, France b- Laboratory of Computational Chemistry and Nanostructures, University of 08 May 45 Guelma, Algeria c- Research Center in Industrial Technology (CRTI), P.O.BOX 64, Chéraga 16014, Algiers, Algeria *corresponding author: [email protected] KEYWORDS: Cyclodextrin. Inclusion complexes. Molecular dynamic simulation. Binding Kinetics. Benzoic acid derivatives. Paracetamol. ABSTRACT This theoretical study is designed to identify the main driving forces of the inclusion of some benzoic acid (BA) derivatives as well as Paracetamol (ParCM) with β-cyclodextrin (β-CD) by computing the kinetics of binding. -
Kohen Curriculum Vitae
Curriculum Vitae Amnon Kohen Department of Chemistry Tel: (319) 335-0234 University of Iowa FAX: (319) 335-1270 Iowa City, IA 52242 [email protected] EDUCATION AND PROFESSIONAL HISTORY Education D.Sc., Chemistry 1989-1994 Technion – Israel Institute of Technology, Haifa, Israel Advisor: Professor T. Baasov Topic: Mechanistic Studies of the Enzyme KDO8P Synthase B.Sc., Chemistry (with Honors) 1986-1989 Hebrew University, Jerusalem, Israel Positions Professor 2010-Present Department of Chemistry, University of Iowa, Iowa City, IA and Molecular and Cellular Biology Program, and MSTP faculty member Associate Professor 2005-2010 Department of Chemistry, University of Iowa, Iowa City, IA and Molecular and Cellular Biology Program Assistant Professor 1999-2005 Department of Chemistry, University of Iowa, Iowa City, IA Postgraduate Researcher 1997-1999 With Professor Judith Klinman Department of Chemistry, University of California, Berkeley Topic: Hydrogen Tunneling in Biology: Alcohol Dehydrogenases Postgraduate Fellow 1995-1997 With Professor Judith Klinman Department of Chemistry, University of California, Berkeley Topic: Hydrogen Tunneling in Biology: Glucose Oxidase Visiting Scholar Fall 1994 With Professor Karen S. Anderson Department of Pharmacology, Yale Medical School, New Haven, CT Kohen, A. Affiliations American Society for Biochemistry and Molecular Biology (ASBMB, 2013 - present) Center for Biocatalysis and Bioprocessing (CBB) University of Iowa (2000-Present) The Interdisciplinary Graduate Program in Molecular Biology, University of Iowa (2003- Present) American Association for the Advancement of Science (AAAS, 2011-present) American Chemical Society (1995-Present) Divisions: Organic Chemistry, Physical Chemistry, Biochemistry Sigma Xi (1997-Present) Protein Society (1996-1998) Honors and Awards • Career Development Award (University of Iowa- 2015-2016) • Graduate College Outstanding Faculty Mentor Award (2015). -
The Molecular Sciences Software Institute
The Molecular Sciences Software Institute T. Daniel Crawford, Cecilia Clementi, Robert Harrison, Teresa Head-Gordon, Shantenu Jha*, Anna Krylov, Vijay Pande, and Theresa Windus http://molssi.org S2I2 HEP/CS Workshop at NCSA/UIUC 07 Dec, 2016 1 Outline • Space and Scope of Computational Molecular Sciences. • “State of the art and practice” • Intellectual drivers • Conceptualization Phase: Identifying the community and needs • Bio-molecular Simulations (BMS) Conceptualization • Quantum Mechanics/Chemistry (QM) Conceptualization • Execution Phase. • Structure and Governance Model • Resource Distribution • Work Plan 2 The Molecular Sciences Software Institute (MolSSI) • New project (as of August 1st, 2016) funded by the National Science Foundation. • Collaborative effort by Virginia Tech, Rice U., Stony Brook U., U.C. Berkeley, Stanford U., Rutgers U., U. Southern California, and Iowa State U. • Total budget of $19.42M for five years, potentially renewable to ten years. • Joint support from numerous NSF divisions: Advanced Cyberinfrastructure (ACI), Chemistry (CHE), Division of Materials Research (DMR), Office of Multidisciplinary Activities (OMA) • Designed to serve and enhance the software development efforts of the broad field of computational molecular science. 3 Computational Molecular Sciences (CMS) • The history of CMS – the sub-fields of quantum chemistry, computational materials science, and biomolecular simulation – reaches back decades to the genesis of computational science. • CMS is now a “full partner with experiment”. • For an impressive array of chemical, biochemical, and materials challenges, our community has developed simulations and models that directly impact: • Development of new chiral drugs; • Elucidation of the functionalities of biological macromolecules; • Development of more advanced materials for solar-energy storage, technology for CO2 sequestration, etc. -
1 Drug Development Working Group Report: Analysis of Existing
Drug Development Working Group Report: Analysis of Existing Strengths, Critical Gaps, and Opportunities for Collaboration May 2014 1. Analysis. Biopharma - Focused on innovation with clinical application. Universities will play an increasingly large role in driving innovation in the biomedical industry for the foreseeable future. In New Jersey, there are several major biopharmaceutical and >350 smaller biotechnology and related companies with one or more employees. The recent integration of Rutgers creates a unique opportunity to align the University’s considerable drug discovery and development strengths. A directed effort of this sort would greatly enhance the capabilities of the University and enable University research to synergize with the biopharma industry, broadly defined. Although there have been shifts, mergers, and acquisitions in the New Jersey biopharma industry, the biopharma industry has continued to thrive. In 2003, the NY/NJ biopharma region had 17 companies with valuation >$100 M; in 2013 this region had still had 16 such companies. Moreover, the region is still vibrant: it continues to be home to large biomedical corporations, startups, entrepreneurs, and the world center for finance and capital. New Jersey also has quality industrial laboratory space, an ecosystem populated by a talented and experienced work force that has made New Jersey the “medicine chest of the world,” and an unparalleled opportunity to combine these factors in biopharma ventures that build on partnerships between Rutgers University and industry. Indeed, the primary difference between now and 15 years ago is that the present industry now is willing to reach out in a highly dynamic fashion. Rutgers is uniquely positioned to step forward as the premier university leader in biomedical innovation and development in the region. -
GROMACS: Fast, Flexible, and Free
GROMACS: Fast, Flexible, and Free DAVID VAN DER SPOEL,1 ERIK LINDAHL,2 BERK HESS,3 GERRIT GROENHOF,4 ALAN E. MARK,4 HERMAN J. C. BERENDSEN4 1Department of Cell and Molecular Biology, Uppsala University, Husargatan 3, Box 596, S-75124 Uppsala, Sweden 2Stockholm Bioinformatics Center, SCFAB, Stockholm University, SE-10691 Stockholm, Sweden 3Max-Planck Institut fu¨r Polymerforschung, Ackermannweg 10, D-55128 Mainz, Germany 4Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, Nijenborgh 4, NL-9747 AG Groningen, The Netherlands Received 12 February 2005; Accepted 18 March 2005 DOI 10.1002/jcc.20291 Published online in Wiley InterScience (www.interscience.wiley.com). Abstract: This article describes the software suite GROMACS (Groningen MAchine for Chemical Simulation) that was developed at the University of Groningen, The Netherlands, in the early 1990s. The software, written in ANSI C, originates from a parallel hardware project, and is well suited for parallelization on processor clusters. By careful optimization of neighbor searching and of inner loop performance, GROMACS is a very fast program for molecular dynamics simulation. It does not have a force field of its own, but is compatible with GROMOS, OPLS, AMBER, and ENCAD force fields. In addition, it can handle polarizable shell models and flexible constraints. The program is versatile, as force routines can be added by the user, tabulated functions can be specified, and analyses can be easily customized. Nonequilibrium dynamics and free energy determinations are incorporated. Interfaces with popular quantum-chemical packages (MOPAC, GAMES-UK, GAUSSIAN) are provided to perform mixed MM/QM simula- tions. The package includes about 100 utility and analysis programs. -
Drug Design Project Tips
Drug Design Project Information and Tips CHEM 162B (2012) Part of your grade in Drug Design courses will come from a development of a “Drug Design Project”. Students who have taken Chem162A will be able to continue their project development; students who have not taken Chem 162A can pick one of the projects developed in past and take it further. Students will present their projects during the annual Drug Design Poster Event. Students taking Chem 162 during the Winter 2011 will be able accomplish three important milestones toward completing the Project. Part of your grade will be based on your success in completing these milestones. The milestones that you are expected to complete during the Spring 2012 are: 1) Characterize a validated protein/nucleic acid target for the disease that you are working on. If the target is an enzyme, describe in detail the reaction it catalyzes. If the target is not an enzyme, describe in detail its physiological role and mode of operation 2) Obtain or create a virtual library of possible drug candidates that are expected to bind to this target and carry out virtual screening to identify best binders 3) Describe adsorption, distribution, metabolism, excretion, and possible toxicity aspects of your drug candidate(s). If appropriate, propose modifications to improve your drug. You are expected to turn in your work on each milestone by the due dates specified; you’ll automatically receive 3 points per each milestone if you submit a significantly developed work by the due date. You will earn extra 5 points if you submit all milestones by the due date. -
Preparation and Characterization of Iridium Hydride and Dihydrogen Complexes Relevant to Biomass Deoxygenation
Preparation and Characterization of Iridium Hydride and Dihydrogen Complexes Relevant to Biomass Deoxygenation Jonathan M. Goldberg A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2017 Reading Committee: D. Michael Heinekey, Chair Karen I. Goldberg, Chair Brandi M. Cossairt Program Authorized to Offer Degree: Department of Chemistry © Copyright 2017 Jonathan M. Goldberg University of Washington Abstract Preparation and Characterization of Iridium Hydride and Dihydrogen Complexes Relevant to Biomass Deoxygenation Jonathan M. Goldberg Chairs of the Supervisory Committee: Professor D. Michael Heinekey Professor Karen I. Goldberg Department of Chemistry This thesis describes the fundamental organometallic reactivity of iridium pincer complexes and their applications to glycerol deoxygenation catalysis. These investigations provide support for each step of a previously proposed glycerol deoxygenation mechanism. Chapter 1 outlines the motivations for this work, specifically the goal of using biomass as a chemical feedstock over more common petroleum-based sources. A discussion of the importance of transforming glycerol to higher value products, such as 1,3-propanediol, is discussed. Chapter 2 describes investigations into the importance of pincer ligand steric factors on the coordination chemistry of the iridium metal center. Full characterization of a five-coordinate iridium-hydride complex is presented; this species was previously proposed to be a catalyst resting state for glycerol deoxygenation. Chapter 3 investigates hydrogen addition to R4(POCOP)Ir(CO) R4 3 t i R4 R4 3 [ POCOP = κ -C6H3-2,6-(OPR2)2 for R = Bu, Pr] and (PCP)Ir(CO) [ (PCP) = κ -C6H3-2,6- t i (CH2PR2)2 for R = Bu, Pr] to give cis- and/or trans-dihydride complexes. -
Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development
processes Review Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development Outi M. H. Salo-Ahen 1,2,* , Ida Alanko 1,2, Rajendra Bhadane 1,2 , Alexandre M. J. J. Bonvin 3,* , Rodrigo Vargas Honorato 3, Shakhawath Hossain 4 , André H. Juffer 5 , Aleksei Kabedev 4, Maija Lahtela-Kakkonen 6, Anders Støttrup Larsen 7, Eveline Lescrinier 8 , Parthiban Marimuthu 1,2 , Muhammad Usman Mirza 8 , Ghulam Mustafa 9, Ariane Nunes-Alves 10,11,* , Tatu Pantsar 6,12, Atefeh Saadabadi 1,2 , Kalaimathy Singaravelu 13 and Michiel Vanmeert 8 1 Pharmaceutical Sciences Laboratory (Pharmacy), Åbo Akademi University, Tykistökatu 6 A, Biocity, FI-20520 Turku, Finland; ida.alanko@abo.fi (I.A.); rajendra.bhadane@abo.fi (R.B.); parthiban.marimuthu@abo.fi (P.M.); atefeh.saadabadi@abo.fi (A.S.) 2 Structural Bioinformatics Laboratory (Biochemistry), Åbo Akademi University, Tykistökatu 6 A, Biocity, FI-20520 Turku, Finland 3 Faculty of Science-Chemistry, Bijvoet Center for Biomolecular Research, Utrecht University, 3584 CH Utrecht, The Netherlands; [email protected] 4 Swedish Drug Delivery Forum (SDDF), Department of Pharmacy, Uppsala Biomedical Center, Uppsala University, 751 23 Uppsala, Sweden; [email protected] (S.H.); [email protected] (A.K.) 5 Biocenter Oulu & Faculty of Biochemistry and Molecular Medicine, University of Oulu, Aapistie 7 A, FI-90014 Oulu, Finland; andre.juffer@oulu.fi 6 School of Pharmacy, University of Eastern Finland, FI-70210 Kuopio, Finland; maija.lahtela-kakkonen@uef.fi (M.L.-K.); tatu.pantsar@uef.fi -
Molecular Cloning, Expression and Enzymatic Assay of Pteridine Reductase 1 from Iranian Lizard Leishmania
Iranian Biomedical Journal 14 (3): 97-102 (July 2010) Molecular Cloning, Expression and Enzymatic Assay of Pteridine Reductase 1 from Iranian Lizard Leishmania Bahram Kazemi*1,2, Farideh Tohidi3,4, Mojgan Bandehpour1 and Fatemeh Yarian1 1Cellular and Molecular Biology Research Center and 2Dept. of Parasitology and Mycology, Shahid Beheshti University, Tehran; 3Dept. of Parasitology and Mycology, Gorgan University of Medical Sciences, Gorgan; 4Bu-Ali Research Institute, Mashhad University of Medical Sciences, Mashhad, Iran Received 17 April 2010; revised 17 July 2010; accepted 24 July 2010 ABSTRACT Background: Currently, there are no effective vaccines against leishmaniasis, and treatment using pentavalent antimonial drugs is occasionally effective and often toxic for patients. The PTR1 enzyme, which causes antifolate drug resistance in Leishmania parasites encoded by gene pteridine reductase 1 (ptr1). Since Leishmania lacks pteridine and folate metabolism, it cannot synthesize the pteridine moiety from guanine triphosphate. Therefore, it must produce pteridine using PTR1, an essential part of the salvage pathway that reduces oxidized pteridines. Thus, PTR1 is a good drug-target candidate for anti-Leishmania chemotherapy. The aim of this study was the cloning, expression, and enzymatic assay of the ptr1 gene from Iranian lizard Leishmania as a model for further studies on Leishmania. Methods: Promastigote DNA was extracted from the Iranian lizard Leishmania, and the ptr1 gene was amplified using specific primers. The PCR product was cloned, transformed into Escherichia coli strain JM109, and expressed. The recombinant protein (PTR1 enzyme) was then purified and assayed. Results: ptr1 gene was successfully amplified and cloned into expression vector. Recombinant protein (PTR1 enzyme) was purified using affinity chromatography and confirmed by Western-blot and dot blot using anti-Leishmania major PTR1 antibody and anti-T7 tag monoclonal antibody, respectively. -
Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma Brucei Pteridine Reductase 1 Daniel Spinks, Han B
MED DOI: 10.1002/cmdc.201000450 Design, Synthesis and Biological Evaluation of Novel Inhibitors of Trypanosoma brucei Pteridine Reductase 1 Daniel Spinks, Han B. Ong, Chidochangu P. Mpamhanga, Emma J. Shanks, David A. Robinson, Iain T. Collie, Kevin D. Read, Julie A. Frearson, Paul G. Wyatt, Ruth Brenk, Alan H. Fairlamb, and Ian H. Gilbert*[a] Genetic studies indicate that the enzyme pteridine reductase 1 chemistry and structure-based approaches, we were able to (PTR1) is essential for the survival of the protozoan parasite Try- derive compounds with potent activity against T. brucei PTR1 app m panosoma brucei. Herein, we describe the development and (K i = 7n ), which had high selectivity over both human and optimisation of a novel series of PTR1 inhibitors, based on ben- T. brucei dihydrofolate reductase. Unfortunately, these com- zo[d]imidazol-2-amine derivatives. Data are reported on 33 pounds displayed weak activity against the parasites. Kinetic compounds. This series was initially discovered by a virtual studies and analysis indicate that the main reason for the lack screening campaign (J. Med. Chem., 2009, 52, 4454). The inhibi- of cell potency is due to the compounds having insufficient tors adopted an alternative binding mode to those of the nat- potency against the enzyme, which can be seen from the low m m ural ligands, biopterin and dihydrobiopterin, and classical in- Km to Ki ratio (Km =25 n and Ki = 2.3 n , respectively). hibitors, such as methotrexate. Using both rational medicinal Introduction Human African trypanosomiasis (HAT) is a serious health prob- lem in sub-Saharan Africa, with an estimated 50 000 new infec- tions each year, and over 60 million people in 36 countries are at risk of infection.[1] HAT is a progressive and ultimately fatal disease. -
Evaluation of Protein-Ligand Docking Methods on Peptide-Ligand
bioRxiv preprint doi: https://doi.org/10.1101/212514; this version posted November 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Evaluation of protein-ligand docking methods on peptide-ligand complexes for docking small ligands to peptides Sandeep Singh1#, Hemant Kumar Srivastava1#, Gaurav Kishor1#, Harinder Singh1, Piyush Agrawal1 and G.P.S. Raghava1,2* 1CSIR-Institute of Microbial Technology, Sector 39A, Chandigarh, India. 2Indraprastha Institute of Information Technology, Okhla Phase III, Delhi India #Authors Contributed Equally Emails of Authors: SS: [email protected] HKS: [email protected] GK: [email protected] HS: [email protected] PA: [email protected] * Corresponding author Professor of Center for Computation Biology, Indraprastha Institute of Information Technology (IIIT Delhi), Okhla Phase III, New Delhi-110020, India Phone: +91-172-26907444 Fax: +91-172-26907410 E-mail: [email protected] Running Title: Benchmarking of docking methods 1 bioRxiv preprint doi: https://doi.org/10.1101/212514; this version posted November 1, 2017. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. ABSTRACT In the past, many benchmarking studies have been performed on protein-protein and protein-ligand docking however there is no study on peptide-ligand docking.